Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
129,337,627
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
39,320,369
-
Shares change
-
+8,136,309
-
Total reported value, excl. options
-
$63,309,166
-
Value change
-
+$10,803,111
-
Put/Call ratio
-
44%
-
Number of buys
-
34
-
Number of sells
-
-47
-
Price
-
$1.60
Significant Holders of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) as of Q4 2021
120 filings reported holding ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock as of Q4 2021.
ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39,320,369 shares
of 129,337,627 outstanding shares and own 30% of the company stock.
Largest 10 shareholders include BlackRock Inc. (9,539,593 shares), VANGUARD GROUP INC (6,970,850 shares), D. E. Shaw & Co., Inc. (4,147,809 shares), TWO SIGMA INVESTMENTS, LP (2,371,193 shares), STATE STREET CORP (2,142,050 shares), CITADEL ADVISORS LLC (2,052,057 shares), GEODE CAPITAL MANAGEMENT, LLC (2,004,781 shares), TWO SIGMA ADVISERS, LP (1,597,930 shares), Nuveen Asset Management, LLC (1,540,502 shares), and RENAISSANCE TECHNOLOGIES LLC (1,170,340 shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.